Prednisolone - Comprehensive Research Paper

Document Information

• Paper Number: 50 of 76
• Category: Corticosteroids - Glucocorticoids
• Last Updated: 2025-12-26
• Status: FDA-APPROVED (since 1955)

1. Summary

Prednisolone is a synthetic glucocorticoid corticosteroid that serves as the biologically active metabolite of prednisone. Unlike prednisone, which is a prodrug requiring hepatic activation, prednisolone is pharmacologically active upon administration, making it the preferred glucocorticoid in patients with hepatic impairment. First FDA-approved in 1955, prednisolone shares the same broad therapeutic applications as prednisone but offers unique formulation advantages including ophthalmic preparations and pediatric-friendly oral solutions.

Prednisolone exerts its effects through glucocorticoid receptor activation, modulating gene transcription to reduce inflammation and suppress immune responses. With an anti-inflammatory potency approximately 4 times that of hydrocortisone, prednisolone is classified as an intermediate-acting corticosteroid with equivalent dosing to prednisone (5 mg prednisolone = 5 mg prednisone = 20 mg hydrocortisone).

Key Distinction from Prednisone:

• Prednisone is a prodrug requiring hepatic conversion via 11β-HSD1 to become active
• Prednisolone is the active form that works directly without requiring liver metabolism
• In patients with severe liver disease, prednisolone may be preferred (though clinical significance is debated)
• Prednisolone is available in formulations not available for prednisone (ophthalmic, ODT)

Clinical Applications: Prednisolone shares all indications with prednisone:

• Endocrine disorders (adrenal insufficiency, congenital adrenal hyperplasia)
• Rheumatic diseases (rheumatoid arthritis, lupus, polymyalgia rheumatica)
• Allergic conditions (severe allergic reactions, asthma exacerbations)
• Dermatologic diseases (pemphigus, severe dermatitis)
• Pulmonary diseases (COPD exacerbations, sarcoidosis)
• Hematologic disorders (autoimmune hemolytic anemia, ITP)
• Neoplastic diseases (as part of chemotherapy regimens)
• Ophthalmic conditions (via topical ophthalmic formulations)
• Pediatric conditions (asthma, nephrotic syndrome - via oral solutions)

Key Characteristics:

• Generic Name: Prednisolone
• Brand Names: Orapred, Orapred ODT, Pediapred, Prelone, Pred Forte (ophthalmic), Omnipred (ophthalmic)
• FDA Approval: 1955
• Drug Class: Synthetic glucocorticoid corticosteroid (active form)
• Prodrug Status: No - directly active
• Potency Ratio: 4:1 anti-inflammatory vs. hydrocortisone
• Mineralocorticoid Activity: Low (0.8 relative to hydrocortisone)
• Half-Life: Plasma 2-4 hours; biological 12-36 hours (intermediate-acting)
• Controlled Substance: No
• Pregnancy Category: C
• Available Formulations: Oral tablets, orally disintegrating tablets, oral solution, ophthalmic suspension/solution

Goal Relevance:

• Manage and reduce inflammation in conditions like rheumatoid arthritis or lupus
• Control and alleviate severe allergic reactions and asthma symptoms
• Support recovery from COPD exacerbations and improve breathing in lung conditions
• Treat skin conditions such as severe dermatitis or pemphigus to reduce discomfort
• Provide relief for autoimmune disorders like autoimmune hemolytic anemia
• Aid in managing eye inflammation and discomfort with ophthalmic solutions
• Support pediatric health by managing asthma or nephrotic syndrome symptoms

2. Mechanism of Action

Prednisolone is a synthetic glucocorticoid that directly activates glucocorticoid receptors without requiring metabolic conversion. As the active metabolite of prednisone, prednisolone has identical pharmacodynamic effects.

Direct Activity (No Prodrug Conversion)

Key Difference from Prednisone:

• Prednisone: Prodrug → Hepatic 11β-HSD1 → Prednisolone (active)
• Prednisolone: Directly active upon absorption

Clinical Implications:

• Immediate pharmacologic activity
• No dependence on liver function for activation
• Theoretically preferred in hepatic impairment (though clinical data mixed)
• Interconversion occurs: Prednisolone ↔ Prednisone (equilibrium in body)

Genomic Mechanisms (Primary)

Glucocorticoid Receptor Activation:

1. Prednisolone crosses cell membranes due to lipophilicity
2. Binds to cytoplasmic glucocorticoid receptors (GR-α)
3. Receptor-ligand complex dissociates from heat shock proteins
4. Complex translocates to the nucleus
5. Binds to glucocorticoid response elements (GREs) on DNA
6. Modulates gene transcription (transactivation and transrepression)

Transactivation (Gene Activation):

• Lipocortin-1 (annexin A1) - inhibits phospholipase A2
• IκBα - inhibits NF-κB signaling pathway
• MAPK phosphatase-1 - deactivates inflammatory signaling
• IL-10 - anti-inflammatory cytokine production
• β2-adrenergic receptors - enhances bronchodilator response

Transrepression (Gene Suppression):

• Pro-inflammatory cytokines: IL-1β, IL-2, IL-6, TNF-α, IFN-γ
• Chemokines: IL-8, RANTES, MCP-1
• Adhesion molecules: ICAM-1, VCAM-1, E-selectin
• Inflammatory enzymes: COX-2, iNOS, phospholipase A2
• Prostaglandins and leukotrienes

NF-κB Pathway Inhibition:

• Direct interaction with NF-κB transcription factor
• Prevents NF-κB DNA binding
• Induces IκBα expression
• Major mechanism of anti-inflammatory action

Non-Genomic Mechanisms

Rapid Effects (seconds to minutes):

• Membrane-associated glucocorticoid receptor effects
• Ion channel modulation
• Second messenger signaling alterations
• Clinically relevant in high-dose/pulse therapy

Immunosuppressive Effects

Cellular Effects:

• Lymphocyte apoptosis induction (especially T cells)
• Lymphocyte redistribution to lymphoid tissue
• Reduced antigen presentation
• Decreased cytokine production
• Impaired neutrophil migration
• Eosinophil apoptosis

Metabolic Effects

Glucose Metabolism:

• Increased hepatic gluconeogenesis
• Peripheral insulin resistance
• Hyperglycemia (diabetogenic)

Protein and Lipid:

• Increased protein catabolism
• Fat redistribution (central obesity)
• May increase lipid levels

Bone and Mineral:

• Decreased intestinal calcium absorption
• Increased renal calcium excretion
• Inhibited osteoblast function
• Osteoporosis with prolonged use

Ophthalmic Mechanism (Topical Use)

Local Effects in Eye:

• Reduces ocular inflammation
• Decreases vascular permeability
• Inhibits inflammatory cell migration
• Suppresses allergic responses
• Stabilizes cellular and lysosomal membranes

3. FDA-Approved Indications

Prednisolone shares the same systemic indications as prednisone, with the addition of ophthalmic indications for topical formulations.

Systemic Indications (Oral)

Endocrine Disorders:

• Primary and secondary adrenocortical insufficiency
• Congenital adrenal hyperplasia
• Hypercalcemia of malignancy
• Nonsuppurative thyroiditis

Rheumatic Disorders:

• Rheumatoid arthritis (including juvenile)
• Psoriatic arthritis, ankylosing spondylitis
• Acute gouty arthritis
• Systemic lupus erythematosus
• Dermatomyositis, polymyositis
• Polymyalgia rheumatica, giant cell arteritis
• Acute bursitis, tenosynovitis

Dermatologic Diseases:

• Pemphigus, bullous dermatitis herpetiformis
• Severe erythema multiforme (Stevens-Johnson syndrome)
• Exfoliative dermatitis, severe psoriasis
• Mycosis fungoides

Allergic States:

• Severe allergic reactions, anaphylaxis
• Bronchial asthma
• Allergic rhinitis (severe)
• Contact and atopic dermatitis
• Drug hypersensitivity reactions
• Serum sickness

Respiratory Diseases:

• Sarcoidosis
• Aspiration pneumonitis
• Berylliosis, Loeffler's syndrome
• COPD exacerbations
• Asthma exacerbations

Hematologic Disorders:

• Idiopathic thrombocytopenic purpura (ITP)
• Autoimmune hemolytic anemia
• Erythroblastopenia, Diamond-Blackfan anemia

Neoplastic Diseases:

• Leukemias and lymphomas (palliative)
• Part of chemotherapy regimens

Gastrointestinal Diseases:

• Ulcerative colitis
• Crohn's disease (regional enteritis)

Renal Diseases:

• Nephrotic syndrome

Nervous System:

• Multiple sclerosis exacerbations
• Cerebral edema

Ophthalmic Indications (Topical)

Pred Forte, Omnipred, and other ophthalmic formulations are indicated for:

Steroid-Responsive Ocular Inflammation:

• Allergic conjunctivitis
• Vernal keratoconjunctivitis
• Keratitis (except herpetic)
• Iritis, iridocyclitis
• Anterior uveitis
• Posterior uveitis and choroiditis
• Optic neuritis
• Sympathetic ophthalmia
• Corneal injury (chemical, thermal, radiation)
• Post-operative inflammation

Note: Ophthalmic corticosteroids require concomitant antimicrobial therapy when bacterial or viral infection is present.

Pediatric-Specific Considerations

Prednisolone oral solutions (Orapred, Pediapred) are commonly used for:

• Acute asthma exacerbations (1-2 mg/kg/day)
• Nephrotic syndrome (60 mg/m²/day)
• Infantile spasms
• Hemangiomas of infancy
• Allergic conditions
• Immunosuppression protocols

4. Dosing and Administration

Prednisolone dosing is equivalent to prednisone on a milligram-for-milligram basis. The choice of prednisolone over prednisone is typically based on formulation needs or patient factors.

Dosage Forms

Oral Tablets:

• 5 mg tablets

Orally Disintegrating Tablets (Orapred ODT):

• 10 mg, 15 mg, 30 mg
• Disintegrate on tongue; may take with or without water
• Contains phenylalanine (important for PKU patients)

Oral Solutions:

• Orapred: 15 mg/5 mL (prednisolone sodium phosphate)
• Pediapred: 5 mg/5 mL (prednisolone sodium phosphate)
• Prelone: 15 mg/5 mL (prednisolone base)
• Generic: Various concentrations (5 mg/5 mL, 15 mg/5 mL)

Ophthalmic Suspension:

• Pred Forte: 1% (prednisolone acetate)
• Pred Mild: 0.12% (prednisolone acetate)
• Omnipred: 1% (prednisolone acetate)

Ophthalmic Solution:

• Various generics (prednisolone sodium phosphate)

Systemic Dosing (Oral)

General Principles:

• Dose equivalent to prednisone (5 mg prednisolone = 5 mg prednisone)
• Individualized based on condition and response
• Use lowest effective dose
• Taper after prolonged use

Adult Dosing by Condition:

Pediatric Dosing:

Ophthalmic Dosing

Pred Forte (1% suspension):

• Instill 1-2 drops into affected eye(s) 2-4 times daily
• May increase to every 1-2 hours during initial therapy for severe inflammation
• Taper gradually; do not discontinue abruptly
• Shake well before use

Post-Operative:

• 1-2 drops QID beginning 24 hours after surgery
• Continue for 2 weeks, then taper

Administration Guidelines

Oral Tablets/Solutions:

• Take with food to minimize GI upset
• Morning dosing preferred (mimics cortisol rhythm)
• Oral solution preferred for accurate pediatric dosing
• ODT: Place on tongue; allow to disintegrate; swallow

Ophthalmic:

• Shake suspension formulations vigorously before each use
• Avoid touching dropper tip to any surface
• Wait 5 minutes between multiple eye medications
• Remove contact lenses before administration
• Do not use if solution changes color or becomes cloudy

Tapering

Required after >2-3 weeks of therapy:

• Gradual reduction prevents adrenal insufficiency
• Taper rate depends on dose and duration
• Typical: Reduce by 10-20% every 1-2 weeks
• Slower tapers for longer therapy durations

5. Pharmacokinetics

Prednisolone has distinct pharmacokinetic advantages over prednisone, particularly its direct activity without hepatic conversion.

Absorption

Oral Bioavailability:

• Tablets: 70-85% (similar to prednisone)
• Solutions: High bioavailability
• Orapred solution: Produces 14% higher peak and 20% faster Tmax than tablets

Tmax (Time to Peak):

• Tablets: 1-2 hours
• Solutions: 1-1.5 hours
• ODT: Similar to tablets

Food Effect:

• May delay but does not significantly reduce absorption
• Take with food to minimize GI effects

Distribution

Protein Binding:

• 70-90% bound to plasma proteins
• Transcortin (CBG): High affinity, low capacity binding
• Albumin: Lower affinity, high capacity binding
• Binding is saturable - free fraction increases at higher doses

Volume of Distribution:

• 0.22-0.7 L/kg
• Widely distributed to tissues
• Crosses blood-brain barrier
• Crosses placenta (partially inactivated by placental 11β-HSD2)
• Excreted in breast milk

Metabolism

No Prodrug Conversion Needed:

• Unlike prednisone, no 11β-HSD1 activation required
• Active upon absorption
• Advantage in severe liver disease (theoretical)

Metabolic Pathways:

• Hepatic metabolism to inactive metabolites
• 6β-hydroxyprednisolone (major metabolite)
• Sulfate and glucuronide conjugation
• CYP3A4 involvement in some pathways
• Interconversion with prednisone occurs (equilibrium)

Hepatic Impairment:

• Historically preferred over prednisone in liver disease
• Recent data suggests prednisone conversion remains adequate even in moderate disease
• May have higher free fraction due to hypoalbuminemia
• Consider starting with lower doses

Elimination

Half-Life:

• Plasma half-life: 2-4 hours (range 2.1-3.5 hours)
• Slightly shorter than prednisone (which must be converted first)
• Half-life shorter in children than adults
• Half-life prolonged in liver disease and elderly

Duration of Action:

• Biological half-life: 12-36 hours
• Intermediate-acting classification
• Allows once-daily dosing

Excretion:

• Renal: Sulfate and glucuronide conjugates in urine
• Minimal unchanged drug in urine (<1%)
• Fecal elimination via bile

Special Populations

Pediatric:

• Faster clearance, shorter half-life than adults
• Weight-based dosing required
• Solutions preferred for accurate dosing

Geriatric:

• Higher plasma concentrations
• Reduced metabolic clearance
• Greater sensitivity to adverse effects
• Start with lower doses

Hepatic Impairment:

• May have prolonged half-life
• Hypoalbuminemia increases free drug fraction
• Preferred over prednisone (no conversion needed)
• Consider dose reduction

Renal Impairment:

• Minimal effect on pharmacokinetics
• No routine dose adjustment required

Drug Interactions (Pharmacokinetic)

CYP3A4 Inducers (Decrease Effect):

• Rifampin (most significant)
• Phenytoin, phenobarbital, carbamazepine
• May require dose increase

CYP3A4 Inhibitors (Increase Effect):

• Ketoconazole, itraconazole
• Ritonavir
• May require dose reduction

Oral Contraceptives/Estrogens:

• Increase transcortin levels
• May prolong half-life and decrease clearance

6. Side Effects and Adverse Reactions

Prednisolone shares the identical adverse effect profile as prednisone, as they represent the same pharmacologically active compound. Effects are dose and duration-dependent.

Short-Term Side Effects (Common)

Metabolic/Endocrine:

• Increased appetite and weight gain
• Fluid retention and edema
• Hyperglycemia (new-onset or worsening diabetes)
• Hypokalemia

Neuropsychiatric:

• Insomnia (very common)
• Mood changes (euphoria, irritability)
• Anxiety and restlessness
• Difficulty concentrating

Gastrointestinal:

• Dyspepsia, heartburn
• Nausea
• Abdominal bloating
• Oral solutions may have taste issues (formulation-dependent)

Cardiovascular:

• Hypertension
• Fluid retention

Dermatologic:

• Facial flushing
• Acne
• Increased sweating

Long-Term Side Effects (Duration >3 Months)

Musculoskeletal:

• Osteoporosis: Most significant long-term risk
  • Bone loss begins within weeks of therapy
  • Significant fracture risk increase at all doses
  • Vertebral fractures most common
• Osteonecrosis (Avascular Necrosis)
• Steroid Myopathy:
  • Proximal muscle weakness
  • Affects hip and shoulder girdle

Endocrine:

• HPA Axis Suppression:
  • Occurs with prolonged use
  • Adrenal insufficiency risk if stopped abruptly
  • May persist months after discontinuation
• Iatrogenic Cushing's Syndrome:
  • Moon facies, buffalo hump
  • Central obesity, striae, skin atrophy
• Diabetes:
  • New-onset or worsened glycemic control

Cardiovascular:

• Hypertension
• Increased cardiovascular disease risk
• Accelerated atherosclerosis

Ophthalmologic:

• Cataracts: Posterior subcapsular
• Glaucoma: Increased intraocular pressure
• Central Serous Chorioretinopathy

Dermatologic:

• Skin atrophy and fragility
• Easy bruising
• Poor wound healing
• Striae, hirsutism, acne

Immunologic:

• Increased Infection Risk
• Opportunistic infections
• Reactivation of latent infections (TB, Hepatitis B)
• Masked infection symptoms

Neuropsychiatric:

• Depression or mania
• Psychosis (especially high doses)
• Cognitive impairment

Other:

• Growth suppression in children
• Menstrual irregularities
• Lipodystrophy

Ophthalmic-Specific Side Effects (Topical)

Local Effects:

• Elevated intraocular pressure (IOP)
• Posterior subcapsular cataract formation
• Delayed wound healing
• Secondary ocular infections
• Corneal thinning and perforation (with prolonged use)
• Mydriasis, ptosis, epithelial defects

Systemic Absorption (Rare with Topical):

• Adrenal suppression (prolonged/frequent use)
• Hyperglycemia

Withdrawal Effects

Adrenal Insufficiency:

• Fatigue, weakness, hypotension
• Hypoglycemia, nausea
• Can be life-threatening

Steroid Withdrawal Syndrome:

• Arthralgias, myalgias
• Fatigue, malaise
• May mimic disease flare

Pediatric-Specific Concerns

Orapred/Pediapred Solutions:

• Taste issues may affect compliance
• Growth suppression with chronic use
• Behavioral changes more prominent
• Monitor height velocity closely

7. Drug Interactions

Prednisolone has the same drug interaction profile as prednisone.

Contraindicated Combinations

Mifepristone:

• Glucocorticoid receptor antagonist
• Negates therapeutic effect

Live Vaccines:

• Risk of disseminated infection
• Avoid during immunosuppressive therapy
• Wait ≥3 months after high-dose therapy

Significant Drug Interactions

CYP3A4 Inducers (Decrease Prednisolone Effect):

CYP3A4 Inhibitors (Increase Prednisolone Effect):

Hormonal Agents:

Pharmacodynamic Interactions

Anticoagulants (Warfarin):

• Variable INR effect
• Monitor closely
• May need warfarin adjustment

Diabetes Medications:

• Prednisolone causes hyperglycemia
• May need increased insulin or oral agent doses
• Close glucose monitoring required

NSAIDs:

• Synergistic GI bleeding risk
• Use gastroprotection if combined

Diuretics:

• Additive hypokalemia (loop, thiazides)
• Monitor potassium

Digoxin:

• Hypokalemia increases digoxin toxicity
• Monitor potassium and digoxin levels

Fluoroquinolones:

• Increased tendon rupture risk
• Particular caution in elderly

Anticholinesterases:

• May cause severe weakness in myasthenia gravis
• Caution with initiation

Antihypertensives:

• Prednisolone causes fluid retention and hypertension
• May reduce antihypertensive efficacy

Ophthalmic Drug Interactions

Topical Ophthalmic Prednisolone:

• Generally minimal systemic absorption
• Additive IOP increase with other glaucoma-exacerbating drugs
• May mask ocular infections; use with antimicrobials when indicated

8. Contraindications

Absolute Contraindications

Systemic (Oral) Prednisolone:

Systemic Fungal Infections:

• Only absolute contraindication
• May cause disseminated fungal disease

Hypersensitivity:

• True allergy to prednisolone or excipients
• Extremely rare

Ophthalmic Prednisolone:

Viral Diseases of Cornea and Conjunctiva:

• Acute superficial herpes simplex keratitis (dendritic keratitis)
• Vaccinia, varicella
• Risk of worsening infection and corneal perforation

Mycobacterial Ocular Infections:

• Untreated TB of eye
• May exacerbate infection

Fungal Diseases of Ocular Structures:

• Risk of exacerbation

Acute Untreated Purulent Ocular Infections:

• Steroids may mask progression

Relative Contraindications (Systemic)

Active Infections:

• Untreated bacterial, viral, or parasitic infections
• Active TB (unless on anti-TB therapy)
• Strongyloides (hyperinfection syndrome risk)

Psychiatric Disorders:

• Active psychosis
• Severe depression
• History of steroid-induced psychiatric symptoms

Gastrointestinal:

• Active peptic ulcer disease
• Diverticulitis
• Fresh intestinal anastomoses

Cardiovascular:

• Uncontrolled hypertension
• Recent myocardial infarction
• Decompensated heart failure

Endocrine:

• Uncontrolled diabetes mellitus
• Cushing's syndrome

Ophthalmologic:

• Ocular herpes simplex (systemic therapy)
• Uncontrolled glaucoma

Musculoskeletal:

• Severe osteoporosis

Other:

• Myasthenia gravis (initiation may cause weakness)

Warnings and Precautions

HPA Axis Suppression:

• Occurs with prolonged use
• Gradual tapering required
• Stress dosing may be needed for up to 1 year post-discontinuation

Immunosuppression:

• Increased infection susceptibility
• Masks infection signs/symptoms
• Screen for latent TB and Hepatitis B

Pediatric Growth:

• Chronic use suppresses growth
• Monitor height velocity
• Use lowest effective dose

Ophthalmic Use:

• Prolonged use increases cataract and glaucoma risk
• Regular IOP monitoring required
• Do not use for self-medication beyond prescribed course

9. Special Populations

Pregnancy

FDA Category C

Placental Transfer:

• Prednisolone crosses the placenta
• Partially inactivated by placental 11β-HSD2 enzyme
• Fetal exposure approximately 10% of maternal level
• Less placental transfer than dexamethasone or betamethasone

Potential Risks:

• First trimester: Historical concern for cleft lip/palate (small increased risk)
• Preterm delivery with long-term use
• Low birth weight, IUGR with high doses
• Gestational diabetes exacerbation
• Neonatal adrenal insufficiency (high maternal doses)

Clinical Practice:

• Many conditions requiring corticosteroids are dangerous if untreated
• Use lowest effective dose
• Risk-benefit assessment required
• Prednisolone is often continued for asthma, lupus, RA during pregnancy

Ophthalmic Use in Pregnancy:

• Minimal systemic absorption expected
• Use if benefit outweighs risk
• Limited data available

Lactation

Breast Milk Excretion:

• Prednisolone is excreted in breast milk
• Infant exposure: ~5-25% of weight-adjusted maternal dose
• Low-to-moderate doses generally compatible with breastfeeding

Recommendations:

• AAP considers compatible with breastfeeding
• At doses >20 mg/day: Consider waiting 4 hours after dose to breastfeed
• Monitor infant for growth and feeding issues

Pediatric

Preferred Formulations:

• Oral solutions (Orapred, Pediapred) ideal for accurate pediatric dosing
• ODT (Orapred ODT) for children who can manage orally disintegrating tablets
• Avoid tablets in young children due to swallowing difficulty

Dosing:

• Weight-based (mg/kg) or surface area-based (mg/m²)
• Asthma: 1-2 mg/kg/day (max 60 mg)
• Nephrotic syndrome: 60 mg/m²/day divided TID
• Croup: 1-2 mg/kg single dose

Special Considerations:

• Growth suppression: Major concern with chronic therapy
  • Monitor height velocity every 3-6 months
  • Use lowest effective dose
  • Consider alternate-day therapy
• Behavioral changes may be pronounced
• Increased infection susceptibility
• Adrenal suppression occurs

Pharmacokinetics:

• Faster clearance than adults
• Shorter half-life
• May require relatively higher weight-based doses

Geriatric

Increased Vulnerabilities:

• Higher plasma concentrations
• Reduced metabolic clearance
• Greater sensitivity to adverse effects

Specific Risks:

• Osteoporosis: Already at risk; steroids accelerate bone loss
• Infections: Increased susceptibility
• Glucose intolerance: Higher diabetes risk
• Cardiovascular: Hypertension, fluid retention
• Cognitive: Delirium risk with high doses
• Falls: Myopathy and bone fragility increase fall risk

Recommendations:

• Start at lower doses
• Slower titration
• Bone protection mandatory (calcium, vitamin D, bisphosphonate consideration)
• Close monitoring for adverse effects

Hepatic Impairment

Key Advantage of Prednisolone:

• Does NOT require hepatic conversion (unlike prednisone)
• Historically preferred in liver disease

Considerations:

• Hypoalbuminemia increases free drug fraction
• May have increased effect per dose
• Half-life may be prolonged

Recommendations:

• Prednisolone preferred over prednisone in significant liver disease
• Start with lower doses
• Monitor for increased adverse effects
• Consider free drug levels (theoretical)

Clinical Note:

• Some pharmacokinetic studies suggest prednisone conversion remains adequate even in moderate liver disease
• Clinical judgment should guide choice

Renal Impairment

Pharmacokinetics:

• Minimal effect on prednisolone elimination
• No routine dose adjustment required
• Hypoalbuminemia (nephrotic syndrome) increases free drug

Recommendations:

• Standard dosing generally appropriate
• Monitor for fluid retention
• Be aware of infection risk in immunocompromised renal patients

10. Monitoring Parameters

Baseline Assessment

Before Initiating Therapy (Especially Long-Term):

1. Blood glucose (fasting glucose or HbA1c)
2. Blood pressure
3. Bone density (DEXA) if expected duration >3 months
4. Ophthalmologic exam (IOP, lens)
5. Electrolytes (potassium, sodium)
6. Lipid panel
7. Weight
8. Height (children)
9. TB screening (PPD or IGRA) if immunosuppressive doses
10. Hepatitis B serology if high doses planned

Ongoing Monitoring

Every Visit:

• Blood pressure
• Weight
• Signs/symptoms of infection
• Mental status and mood
• Glycemic control
• Cushingoid features

Periodic Laboratory:

Long-Term Monitoring:

Bone Health Protection

For All Patients on ≥3 Months Therapy:

• Calcium: 1000-1200 mg/day
• Vitamin D: 600-800 IU/day (more if deficient)
• Weight-bearing exercise
• Fall risk assessment
• Consider bisphosphonate if T-score <-1.0 or high fracture risk

Ophthalmic Monitoring (Topical Use)

During Topical Prednisolone:

• Intraocular pressure: Baseline and periodic monitoring
• Signs of infection (worsening symptoms, purulent discharge)
• Visual acuity
• Slit-lamp examination for cataract and corneal changes
• Limit duration of therapy when possible

Pediatric-Specific Monitoring

• Height velocity every 3-6 months
• Growth charts documentation
• Behavioral assessment
• Consider bone age if growth concerns

Adrenal Function Monitoring

After Prolonged Therapy:

• Morning cortisol before final discontinuation
• ACTH stimulation test if insufficiency suspected
• Educate on stress dosing needs

Signs Requiring Immediate Attention

• Fever or signs of infection
• Significant mood changes or psychosis
• Severe abdominal pain
• Visual changes
• Bone pain (possible fracture or osteonecrosis)
• Symptoms of adrenal insufficiency during tapering

11. Cost and Availability

Current US Availability

Prednisolone is widely available in multiple formulations, with generic options for most products.

Formulations Available

Oral Tablets:

• 5 mg tablets (generic)
• Multiple generic manufacturers

Orally Disintegrating Tablets (ODT):

• Orapred ODT: 10 mg, 15 mg, 30 mg (brand)
• Generic ODT available

Oral Solutions:

• Pediapred: 5 mg/5 mL (brand - prednisolone sodium phosphate)
• Orapred: 15 mg/5 mL (brand - prednisolone sodium phosphate)
• Prelone: 15 mg/5 mL (brand - prednisolone base)
• Multiple generic solutions available

Ophthalmic Suspension:

• Pred Forte: 1% (brand - prednisolone acetate)
• Pred Mild: 0.12% (brand)
• Omnipred: 1% (brand)
• Multiple generic 1% suspensions

Ophthalmic Solution:

• Generic prednisolone sodium phosphate 1%

Pricing

Oral Tablets (Generic 5 mg):

Orally Disintegrating Tablets:

Oral Solutions:

Ophthalmic Products:

Insurance Coverage

Generic Oral Products:

• Widely covered with low copays
• Tier 1 on most formularies
• No prior authorization typically required

Brand Oral Products (Orapred, Orapred ODT):

• Higher tier (Tier 2-3)
• May require prior authorization
• Step therapy (generic first) often required

Ophthalmic Products:

• Generic suspensions well covered
• Brand (Pred Forte) may require higher copay
• Specialty ophthalmology coverage may apply

Comparison with Prednisone Cost

Recent FDA Approvals

June 2025: Amneal Pharmaceuticals received FDA approval for prednisolone acetate ophthalmic suspension 1% (generic Pred Forte), with commercial launch planned Q3 2025.

Access Programs

Manufacturer Assistance:

• Various patient assistance programs for brand products
• Co-pay cards for eligible patients

Discount Programs:

• GoodRx, SingleCare, RxSaver
• $4 generic lists at retail pharmacies (tablets)

12. Clinical Evidence Summary

Historical Development

Discovery and Approval:

• Prednisolone developed alongside prednisone in the 1950s
• FDA approved in 1955
• As the active metabolite of prednisone, shares identical clinical evidence base for systemic indications

Key Clinical Evidence (Systemic Use)

Shared Evidence with Prednisone: All systemic clinical trial evidence for prednisone applies directly to prednisolone given their pharmacologic equivalence. See Prednisone research paper for detailed trial information.

Prednisolone-Specific Studies:

Hepatic Impairment:

• Historical preference for prednisolone in liver disease based on theoretical avoidance of hepatic conversion
• However, pharmacokinetic studies show prednisone conversion remains adequate even in moderate hepatic impairment
• Clinical significance of prednisolone preference is debated

Pediatric Asthma:

• Extensive evidence supporting oral prednisolone for acute asthma exacerbations
• NHLBI Guidelines: 1-2 mg/kg/day (max 60 mg)
• Solutions preferred for accurate pediatric dosing
• Short courses (3-10 days) do not require tapering

Nephrotic Syndrome in Children:

• Standard initial therapy: 60 mg/m²/day divided TID for 4 weeks
• Then alternate-day therapy for 4 weeks
• Well-established evidence from multiple trials

Ophthalmic Evidence

Pred Forte and Ophthalmic Prednisolone:

Post-Operative Inflammation:

• Extensive evidence for reduction of post-operative ocular inflammation
• Standard of care after cataract surgery, corneal procedures, other eye surgeries
• Typically used QID for 1-4 weeks with tapering

Uveitis and Anterior Segment Inflammation:

• Effective for anterior uveitis, iritis, iridocyclitis
• Often combined with cycloplegics
• May require higher frequency dosing initially

Allergic Conjunctivitis:

• Effective for severe allergic eye disease
• Short-term use preferred due to adverse effect risk

Corneal Injury:

• May accelerate healing and reduce scarring
• Used after chemical burns, thermal injury

Formulation Comparisons

Solutions vs. Tablets (Bioavailability):

• Orapred solution: 14% higher peak and 20% faster Tmax than tablets
• Solutions may provide faster onset
• Solutions preferred for pediatric dosing accuracy

Acetate vs. Phosphate (Ophthalmic):

• Prednisolone acetate: Better corneal penetration, more potent
• Prednisolone phosphate: Soluble, less tissue penetration
• Acetate (Pred Forte) preferred for most inflammatory conditions

13. Comparison with Alternatives

Prednisolone vs. Prednisone

When to Choose Prednisolone:

• Severe hepatic impairment (theoretical advantage)
• Need for liquid formulation (pediatric, dysphagia)
• Need for ODT formulation
• Ophthalmic use (prednisolone only)

When to Choose Prednisone:

• Cost considerations (slightly cheaper tablets)
• Most adult patients with normal liver function
• When formulation doesn't matter

Prednisolone vs. Other Corticosteroids

Potency and Duration Comparison:

Ophthalmic Prednisolone vs. Alternatives

Selection Factors:

• Pred Forte (acetate 1%): Gold standard for most anterior segment inflammation
• Fluorometholone/Loteprednol: When concerned about IOP rise
• Dexamethasone/Difluprednate: Severe inflammation, post-operative

14. Storage and Handling

Storage Requirements

Oral Tablets:

• Store at controlled room temperature: 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F)
• Protect from moisture
• Keep in original container

Orally Disintegrating Tablets (Orapred ODT):

• Store at 20-25°C (68-77°F)
• Keep in blister package until ready to use
• Protect from moisture
• Handle with dry hands

Oral Solutions:

• Orapred, generic phosphate solutions: Refrigerate at 2-8°C (36-46°F)
• Pediapred: May store at 4-25°C; may refrigerate
• Prelone (base): Room temperature
• Protect from light
• Do not freeze

Ophthalmic Products:

• Store at 8-24°C (46-75°F) or per product labeling
• Protect from light
• Keep bottle tightly closed
• Do not freeze
• Discard 28 days after opening (general ophthalmic guidance)

Stability Considerations

Solutions:

• Check expiration date
• Do not use if discolored or cloudy
• Follow specific refrigeration requirements
• Use within labeled timeframe after opening

Ophthalmic Suspensions:

• Shake vigorously before each use
• Particles must be evenly dispersed
• Discard if solution appears contaminated or damaged

Handling Precautions

Oral Solutions:

• Use calibrated measuring device (not household spoon)
• Measure accurately for pediatric dosing
• Some solutions contain alcohol (check product)

ODT:

• Remove from blister pack with dry hands
• Do not push through foil
• Place on tongue immediately
• Allow to disintegrate; may swallow with or without water
• Contains phenylalanine (PKU warning)

Ophthalmic:

• Shake suspension formulations vigorously
• Avoid touching dropper tip to eye or any surface
• Do not use with contact lenses in place
• Wait 5 minutes between different eye drops
• Wash hands before and after use

Disposal

Proper Disposal:

• Medication take-back programs preferred
• If unavailable: Mix with undesirable substance, place in sealed container, dispose in trash
• Do not flush liquid medications
• Follow local regulations

15. Goal Archetype Integration (Glucocorticoid)

Prednisolone belongs to the glucocorticoid archetype within the broader corticosteroid class. Understanding its archetype positioning enables precise protocol design and goal alignment.

Glucocorticoid Archetype Characteristics

Primary Archetype: Glucocorticoid (anti-inflammatory, immunosuppressive) Secondary Archetype: Minimal mineralocorticoid (0.8 relative potency vs. hydrocortisone)

Archetype Comparison Matrix:

Goal Alignment Framework

Anti-Inflammatory Goals (Primary Indication):

• Prednisolone's 4:1 potency ratio (vs. hydrocortisone) makes it the archetypal choice for:
  • Moderate-to-severe inflammatory conditions
  • Autoimmune disease management
  • Acute flare suppression
• Sweet spot between potency and manageable adverse effect profile

Immunosuppression Goals:

• Intermediate positioning allows dose titration for immunomodulation
• Can achieve immunosuppressive doses (>20 mg/day) without extreme potency concerns
• Preferred over dexamethasone when prolonged immunosuppression needed (less HPA suppression per anti-inflammatory unit)

Replacement/Physiologic Goals:

• NOT the archetypal choice for adrenal replacement (hydrocortisone preferred)
• If used for replacement: 5 mg prednisolone ≈ 20 mg hydrocortisone (physiologic equivalent)
• Lacks the mineralocorticoid effect needed for complete adrenal replacement

Stress Response Augmentation:

• Intermediate duration allows flexible stress dosing
• Useful for perioperative stress coverage when already on chronic prednisolone
• Stress dose: 2-3x maintenance or 50-100 mg hydrocortisone equivalent

Archetype-Based Protocol Considerations

When Prednisolone Archetype is Optimal:

1. Need sustained anti-inflammatory effect without extreme potency
2. Hepatic impairment (direct activity advantage)
3. Pediatric populations (liquid formulations)
4. Conditions requiring dose flexibility and tapering
5. Long-term management with goal of eventual discontinuation

When to Consider Alternative Archetypes:

1. Need maximum anti-inflammatory potency → Dexamethasone archetype
2. Physiologic replacement → Hydrocortisone archetype
3. IV pulse therapy → Methylprednisolone archetype
4. Need mineralocorticoid effect → Add fludrocortisone

Goal-Specific Dosing Tiers

16. Age-Stratified Dosing

Age significantly impacts prednisolone pharmacokinetics, pharmacodynamics, and risk-benefit calculations. This section provides age-stratified dosing guidance beyond the standard population recommendations.

Pediatric Age Stratification

Neonates (0-28 days):

• Limited data; typically dexamethasone preferred for specific indications (e.g., BPD)
• If prednisolone used: 0.5-2 mg/kg/day (cautious dosing)
• Higher volume of distribution, immature metabolism
• Significant HPA suppression risk

Infants (1-12 months):

• Faster clearance than adults but immature hepatic function
• Dosing: 0.5-2 mg/kg/day based on indication
• Liquid formulation essential (Pediapred 5 mg/5 mL preferred for accurate dosing)
• Monitor feeding, growth parameters closely

Toddlers/Preschool (1-5 years):

• Rapid metabolism; may require relatively higher mg/kg doses
• Asthma exacerbation: 1-2 mg/kg/day (max 40-60 mg)
• Nephrotic syndrome: 60 mg/m²/day (max 80 mg)
• Behavioral side effects prominent; warn parents
• Growth velocity monitoring essential if therapy >2 weeks

School Age (6-12 years):

• Metabolism approaching adult patterns
• Weight-based dosing: 1-2 mg/kg/day for acute conditions
• Transition to surface area dosing for chronic conditions
• Can use ODT formulations; assess swallowing capability
• Academic/behavioral monitoring during therapy

Adolescents (13-17 years):

• Adult-like pharmacokinetics
• Consider transition to adult dosing for larger adolescents
• Acne exacerbation common (cosmetically distressing)
• Mood/psychiatric effects may be pronounced
• Growth plate monitoring if chronic therapy

Adult Age Stratification

Young Adults (18-40 years):

• Standard adult dosing applies
• Peak bone mass still accruing until ~30 years
• Aggressive bone protection if therapy >3 months
• Fertility considerations: temporary menstrual irregularities, sperm quality effects

Middle Age (40-65 years):

• Standard adult dosing
• Increased metabolic syndrome risk
• Closer glucose monitoring (emerging diabetes risk)
• Bone density baseline recommended if anticipated chronic use
• Cardiovascular risk assessment

Geriatric (65-75 years):

• Consider 20-30% dose reduction for initiation
• Reduced renal function may alter free drug levels
• Enhanced sensitivity to adverse effects
• Osteoporosis risk extremely high; mandatory bone protection
• Delirium risk with higher doses

Advanced Age (>75 years):

• Start low, go slow: 25-50% of typical adult doses initially
• Polypharmacy interaction risk highest
• Fall risk from myopathy + osteoporosis
• Cognitive effects may mimic dementia
• Caregiver education essential

Age-Stratified Dosing Quick Reference

Acute Asthma Exacerbation:

COPD Exacerbation (Adults):

Chronic Inflammatory Disease Maintenance:

Age-Specific Monitoring Adjustments

17. Drug Interactions (Expanded)

This section expands on Section 7 with clinically actionable interaction management and quantitative impact data.

Critical Interactions Requiring Dose Adjustment

CYP3A4 Inducers (Decrease Prednisolone Effect):

CYP3A4 Inhibitors (Increase Prednisolone Effect):

Pharmacodynamic Interactions

Glucose-Elevating Combinations:

Electrolyte-Disturbing Combinations:

Bleeding Risk Combinations:

Musculoskeletal Toxicity:

Disease-State Interaction Considerations

Diabetes Mellitus:

• Prednisolone will increase glucose 50-150 mg/dL or more
• Anticipate 20-50% increase in insulin requirements
• Consider sliding scale coverage during burst therapy
• Monitor fasting and post-prandial glucose

Hypertension:

• Expect 5-15 mmHg increase in blood pressure
• May require antihypertensive intensification
• Sodium retention contributes; dietary counseling helpful

Heart Failure:

• Fluid retention may precipitate decompensation
• Weigh daily during initiation
• Consider lower mineralocorticoid activity alternatives

Osteoporosis:

• Already at fracture threshold: bisphosphonate mandatory
• Calcium 1200 mg + Vitamin D 2000 IU daily
• Consider anabolic agents (teriparatide) if severe

Vaccination Interactions

Immunosuppressive Dose Definition: ≥20 mg/day prednisone equivalent for ≥2 weeks

18. Bloodwork Impact

Prednisolone significantly alters multiple laboratory parameters. Understanding these changes prevents misdiagnosis and enables appropriate clinical interpretation.

Complete Blood Count (CBC) Changes

White Blood Cell Count:

• Leukocytosis: 10,000-20,000/µL common (may exceed 20,000)
• Mechanism: Demargination of neutrophils + lymphocyte redistribution
• Neutrophilia: Predominant; absolute neutrophil count rises
• Lymphopenia: Characteristic; absolute lymphocyte count falls
• Eosinopenia: Consistent finding; diagnostic for cortisol effect
• Monocytopenia: Variable

Clinical Interpretation:

• Do NOT interpret steroid-induced leukocytosis as infection
• Absence of expected leukocytosis in acute illness may indicate adrenal insufficiency
• Left shift (bands, immature forms) suggests true infection despite elevated WBC

Time Course:

• WBC elevation begins within 4-6 hours of dosing
• Peaks at 4-8 hours
• Returns toward baseline by 24 hours (single dose)
• Sustained elevation with daily dosing

Metabolic Panel Changes

Glucose:

• Fasting glucose: May increase 20-100+ mg/dL
• Postprandial: More pronounced elevation
• HbA1c: Increases 0.5-2% with chronic therapy
• New-onset diabetes in 10-20% of chronic users

Electrolytes:

• Potassium: Decreases 0.2-0.5 mEq/L (hypokalemia)
• Sodium: May increase (fluid retention, rarely hypernatremia)
• Chloride: Follows sodium
• Bicarbonate: May increase (metabolic alkalosis)

Renal Function:

• BUN: May increase (protein catabolism)
• Creatinine: Generally stable; may mask renal impairment
• GFR: May appear improved due to increased filtration

Lipid Panel Changes

Endocrine Panel Alterations

Cortisol Axis:

• Morning cortisol: Suppressed (may be undetectable)
• ACTH: Suppressed
• DHEA-S: May be reduced
• Cosyntropin stimulation test: Blunted response if suppressed

Thyroid Function:

• TSH: Generally unchanged
• Free T4: Variable; may affect binding proteins
• T3: May decrease peripheral conversion

Sex Hormones:

• Testosterone: May decrease
• Estrogen: Variable
• FSH/LH: May be suppressed
• Menstrual irregularity common

Coagulation Parameters

Inflammatory Markers

Critical Note: Steroid therapy masks inflammatory markers. In sepsis evaluation:

• Procalcitonin preferred over CRP
• Lactate remains reliable
• Clinical assessment paramount

Bone Markers

Urinalysis Changes

• Glycosuria: Common with hyperglycemia
• Proteinuria: May increase (glomerular effects)
• WBCs in urine: May be masked

Drug Level Monitoring Considerations

Recommended Monitoring Schedule

During Acute Therapy (≤2 weeks):

• Blood glucose: Daily if diabetic; every 2-3 days otherwise
• Electrolytes: Baseline and end of therapy
• CBC: Not routinely needed unless concern for infection

During Chronic Therapy (>3 months):

19. Protocol Integration (Prednisolone vs. Prednisone & Hepatic Conversion)

This section provides detailed guidance on selecting between prednisolone and prednisone, with emphasis on the hepatic conversion pathway and clinical decision-making.

The Prednisone-Prednisolone Interconversion

Biochemical Pathway:

Prednisone (inactive prodrug)
      ↓
   11β-HSD1 (Hepatic enzyme: 11β-hydroxysteroid dehydrogenase type 1)
      ↓
Prednisolone (active glucocorticoid)
      ↓
   11β-HSD2 (Peripheral tissues - kidney, placenta)
      ↓
Prednisone (inactivation in some tissues)

Key Points:

• Prednisone and prednisolone exist in equilibrium in the body
• 11β-HSD1 converts prednisone → prednisolone (activation)
• 11β-HSD2 converts prednisolone → prednisone (inactivation)
• Both enzymes are bidirectional; net effect depends on tissue expression

Hepatic Conversion Efficiency

Normal Liver Function:

• Prednisone → Prednisolone conversion: 80-90% efficient
• Peak prednisolone after prednisone dose: 1-2 hours
• Bioequivalence essentially 1:1 for clinical dosing

Mild Hepatic Impairment (Child-Pugh A):

• Conversion remains adequate (70-85%)
• No dose adjustment typically required
• Either prednisone or prednisolone acceptable

Moderate Hepatic Impairment (Child-Pugh B):

• Conversion reduced but variable (50-70%)
• Prednisolone theoretically preferred
• Clinical significance debated in literature
• Hypoalbuminemia increases free drug → may offset reduced conversion

Severe Hepatic Impairment (Child-Pugh C):

• Significantly impaired conversion (<50%)
• Prednisolone clearly preferred
• Reduce dose due to increased free fraction
• Start with 50-75% of typical dose

Clinical Decision Algorithm

Patient requires intermediate-acting corticosteroid
            ↓
┌─────────────────────────────────────────┐
│ Assess hepatic function                 │
└─────────────────────────────────────────┘
            ↓
     ┌──────┴──────┐
     ↓             ↓
  Normal       Impaired
     ↓             ↓
┌─────────┐   ┌─────────────────────────┐
│ Either  │   │ Mild: Either acceptable │
│ agent   │   │ Mod: Prednisolone pref  │
│ OK      │   │ Severe: Prednisolone    │
└─────────┘   └─────────────────────────┘
            ↓
     ┌──────┴──────┐
     ↓             ↓
  Adult        Pediatric
     ↓             ↓
┌─────────┐   ┌─────────────────────────┐
│ Tablets │   │ Prednisolone solutions  │
│ cheapest│   │ preferred (Orapred,     │
│ option  │   │ Pediapred)              │
└─────────┘   └─────────────────────────┘
            ↓
     ┌──────┴──────┐
     ↓             ↓
  Swallow      Swallowing
  OK           Difficulty
     ↓             ↓
┌─────────┐   ┌─────────────────────────┐
│ Tablets │   │ Prednisolone ODT or     │
│         │   │ solution                │
└─────────┘   └─────────────────────────┘
            ↓
     ┌──────┴──────┐
     ↓             ↓
  Systemic     Ocular
  Route        Use
     ↓             ↓
┌─────────┐   ┌─────────────────────────┐
│ Pred or │   │ Prednisolone ophthalmic │
│ Predni- │   │ (only option)           │
│ solone  │   │                         │
└─────────┘   └─────────────────────────┘

Indications Favoring Prednisolone

Indications Favoring Prednisone

Protocol Equivalence Table

Switching Between Agents

Prednisone to Prednisolone:

• Direct 1:1 substitution
• No washout or overlap needed
• Consider when hepatic function worsens

Prednisolone to Prednisone:

• Direct 1:1 substitution
• Verify hepatic function adequate
• Common when transitioning from pediatric to adult care

To/From Methylprednisolone:

• Use 5:4 ratio (5 mg prednisone/prednisolone = 4 mg methylprednisolone)
• Methylprednisolone has less mineralocorticoid activity
• IV methylprednisolone for pulse therapy; transition to oral pred(nisol)one

To/From Dexamethasone:

• Use 5:0.75 ratio (5 mg prednisone/prednisolone = 0.75 mg dexamethasone)
• Dexamethasone has longer duration; once-daily dosing
• Dexamethasone for severe inflammation, cerebral edema, antiemetic protocols

Special Protocol Considerations

Alternate-Day Therapy:

• Aim: Reduce HPA suppression and adverse effects
• Protocol: Double daily dose every other morning
• Example: Instead of 10 mg daily → 20 mg every other day
• Not suitable for conditions requiring consistent anti-inflammatory effect
• Prednisolone and prednisone equivalent for alternate-day protocols

Stress Dosing Protocol:

• Minor stress (dental procedure): No change if <10 mg/day chronic
• Moderate stress (surgery): 25-50 mg hydrocortisone equivalent day of procedure
• Major stress (ICU illness): 100-150 mg hydrocortisone equivalent per day
• Resume baseline as stress resolves

Tapering Protocols:

20. References

Primary Literature

1. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19(2):126-146.

2. Pickup ME. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1979;4(2):111-128.

3. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.

4. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.

5. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515-1526.

Clinical Guidelines

6. Expert Panel Working Group of the National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma (EPR-3). NIH Publication No. 07-4051. 2007.

7. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.

8. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521-1537.

Drug Information Resources

9. Prednisolone [package insert]. Various manufacturers.

10. Orapred ODT (prednisolone sodium phosphate) [package insert]. Concordia Pharmaceuticals.

11. Pediapred (prednisolone sodium phosphate) [package insert]. Sanofi-Aventis.

12. Pred Forte (prednisolone acetate ophthalmic suspension) [package insert]. Allergan.

13. Prednisolone. In: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc.

14. Prednisolone. In: AHFS Drug Information. American Society of Health-System Pharmacists.

15. DrugBank Online. Prednisolone. https://go.drugbank.com/drugs/DB00860

16. StatPearls [Internet]. Prednisone. National Center for Biotechnology Information.

Ophthalmic Literature

17. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33-55.

18. Leibowitz HM. Clinical evaluation of prednisolone acetate ophthalmic suspension in ocular inflammation. Am J Ophthalmol. 1977;83(6):857-861.

19. Comstock TL, Sheppard JD. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opin Pharmacother. 2018;19(12):1377-1393.

Pharmacokinetics

20. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98.

21. Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm. 1981;9(4):389-417.

22. Rocci ML Jr, Jusko WJ. Dose-dependent protein binding of prednisolone: a bioavailability study of prednisolone preparations. J Pharm Sci. 1981;70(9):1041-1043.

Pediatric Literature

23. Oommen A, Patel R, Browning N, Hashmi MH. Systemic corticosteroids for acute asthma exacerbations in children. Paediatr Respir Rev. 2021;40:28-33.

24. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2007;(4):CD001533.

25. Russell K, Wiebe N, Saenz A, et al. Glucocorticoids for croup. Cochrane Database Syst Rev. 2011;(1):CD001955.

Document Footer

Document Completion: 2025-12-26 Status: PAPER 50 OF 76 COMPLETE Next Paper: #51 - Dexamethasone

Clinical Notes: Prednisolone is pharmacologically equivalent to prednisone and can be used interchangeably on a milligram-for-milligram basis. The key advantages of prednisolone are: (1) direct activity without hepatic conversion, making it theoretically preferred in liver disease; (2) availability of pediatric-friendly liquid formulations; (3) orally disintegrating tablet option; and (4) ophthalmic formulations for ocular inflammation. For most adult patients with normal hepatic function, choice between prednisone and prednisolone is largely based on cost, formulation preference, and clinical custom.

This research paper is part of a comprehensive HRT/hormone product documentation project for Epiq Aminos clinical reference materials.